Rapid Brush Biopsy Test Detects Oral Cancer in One Hour

Oral squamous cell carcinoma (OSCC) is often diagnosed late, when outcomes are poor and treatment is more invasive. Current diagnostic pathways rely on scalpel biopsies that are painful, can introduce complications, and are hard to repeat for surveillance. Clinicians need noninvasive tools to triage suspicious lesions and monitor oral potentially malignant disorders (OPMDs) over time. A new study shows a brush-based molecular test can detect oral cancer in one hour and substantially reduce unnecessary tissue biopsies.

Researchers at Queen Mary University of London validated qMIDS-V3, a noninvasive brush biopsy assay that detects OSCC from exfoliated oral cells within one hour. The test adapts a previously successful microbiopsy multigene assay (qMIDS‑V2) into a rapid oral brush format. According to the study, qMIDS‑V3 enabled accurate OSCC detection while offering a procedure that can be repeated for longitudinal surveillance.

The investigation asked whether the qMIDS‑V2 multigene signature could be transferred from a 1‑millimeter tissue microbiopsy to a brush sample without sacrificing performance. Findings indicate the brush-based version performs comparably to the microbiopsy predecessor. Because no tissue is removed, the method is positioned to support routine monitoring of persistent OPMDs while minimizing patient harm.

This was the largest study of its kind, comprising more than 1,000 samples from 545 patients in a diagnostic case–control design. Prior work with qMIDS‑V2 had been validated across more than 530 samples from the U.K., India, and China, establishing robustness of the underlying multigene signature across diverse settings. The current results were published in Biomarker Research on June 23, 2026.

The authors state that qMIDS‑V3 could spare more than 90% of low‑risk OPMD patients from unnecessary invasive scalpel biopsies and could reduce referrals for more than 90% of cancer‑free patients. Audit data cited from the U.K. highlight substantial overreferral and inefficiency in existing pathways, underscoring the need for rapid, repeatable triage tools. Collaborating institutions included Queen Mary University of London’s Centre for Oral Immunobiology & Regenerative Medicine, King George’s Medical University (India), Modern Dental College & Research Centre (India), and the All India Institute of Medical Sciences.

“Oral cancer survival is directly linked to how early it is found, yet our current diagnostic pathway is blunt—most patients with a suspicious lesion end up having an invasive biopsy even when the overwhelming likelihood is that it is benign. This test changes that. It gives clinicians a rapid, accurate and noninvasive way to triage patients, and crucially, it can be repeated. That means we can now monitor patients with persistent pre-malignant lesions regularly and systematically—and pick up cancers much earlier than we would have been able to before,” said Muy-Teck Teh, professor of molecular oral oncology at Queen Mary.

“We were genuinely astonished by the fact that the brush swab test performance is comparable to a microbiopsy. It suggests that the biological signal captured by these four genes is sufficiently strong and consistent that it can be detected even from the superficial exfoliated cells collected by a brush biopsy. The clinical implications are significant: Patients no longer need even a minimally invasive procedure to benefit from molecularly guided triage,” added Teh.

Related Links
Queen Mary University of London